Longevity Pioneer Alex Zhavornkov commits all his wealth to Longevity

Biotech and longevity pioneer Alex Zhavoronkov has formally announced a personal Longevity Pledge to commit all his remaining time, wealth, and resources to creating and supporting research and clinical solutions that will extend healthy productive longevity to everyone on the planet. 

He has also appealed to other altruistic billionaires and successful founders to dedicate themselves to the “Longevity Pledge” 

“Making productive longevity, or the ability to live a longer, healthier life, is the most altruistic cause you can support. If we could extend everyone’s life by just one more high-quality, healthy year, our world would benefit from roughly 8 billion more impactful years in a few generations.”

According to Zhavoronkov, these additional years could translate to thousands of new medical and scientific discoveries, spur decisive action on climate change, and so much more. He believes that there is no time to waste, and he hopes that by his example, he will motivate others to commit their wealth, intellect, and ingenuity to this highly underappreciated cause. 

Some features of Xhavoronkov’s personal Longevity Pledge include

• Dedicating his entire fortune and his future earnings to the humanitarian cause of longevity. 
• Committing 100% of his time to creating, discovering, advising, and pursuing longevity projects. 
• Investing strictly in companies and businesses that have the potential to improve on a healthy and productive life, translating to a vibrant global longevity ecosystem. As such, these companies will be able to grow and become sustainable, and their profits reinvested into other longevity opportunities.

By inviting others to join his Longevity Pledge, Zhavoronkov is confident that his four significant targets of human longevity can make amazing breakthroughs whose influence will be felt as early as 5 years from now. 

To narrow it down, Zhavoronkov is hoping to develop AI-powered drug discovery platforms that will significantly derisk, accelerate, and democratize the discovery of new anti-aging therapies. As we speak, the cost of drug discovery and development can exceed $3 billion just to launch one new drug on the market. Also, it can take up to 12 years to develop a drug and launch it, with 99% of these drugs failing most of the time. 

He also calls on a greater emphasis on personalized medicine, treatment and drugs. He hopes that we can achieve this by developing fully automated systems that can customize care for each patient and assist in discovering new therapies. 

Zhavoronkov also encourages adopting cryotherapy and biostasis. Recent advancements in technology can now allow doctors to freeze and unfreeze organs quickly, and perhaps even entire bodies, to enable the long-term storage, transportation, and biostasis of the terminally ill. 

Last but not least, to spur hospitals that are powered by artificial intelligence and robotics. This will support the creation of new research and clinical infrastructure for medical care and repair. In fact, Zhavoronkov’s ultimate goal is to create an AI/robotics-driven preventive and regenerative research hospital.